Abstract
Modeling factors influencing disease phenotypes, from biomarker profiling study datasets, is a critical task in biomedicine. Such datasets are typically generated from high-throughput 'omic' technologies, which help examine disease mechanisms at an unprecedented resolution. These datasets are challenging because they are high-dimensional. The disease mechanisms they study are also complex because many diseases are multifactorial, resulting from the collective activity of several factors, each with a small effect. Bayesian rule learning (BRL) is a rule model inferred from learning Bayesian networks from data, and has been shown to be effective in modeling high-dimensional datasets. However, BRL is not efficient at modeling multifactorial diseases since it suffers from data fragmentation during learning. In this paper, we overcome this limitation by implementing and evaluating three types of ensemble model combination strategies with BRL- uniform combination (UC; same as Bagging), Bayesian model averaging (BMA), and Bayesian model combination (BMC)- collectively called Ensemble Bayesian Rule Learning (EBRL). We also introduce a novel method to visualize EBRL models, called the Bayesian Rule Ensemble Visualizing tool (BREVity), which helps extract interpret the most important rule patterns guiding the predictions made by the ensemble model. Our results using twenty-five public, high-dimensional, gene expression datasets of multifactorial diseases, suggest that, both EBRL models using UC and BMC achieve better predictive performance than BMA and other classic machine learning methods. Furthermore, BMC is found to be more reliable than UC, when the ensemble includes sub-optimal models resulting from the stochasticity of the model search process. Together, EBRL and BREVity provides researchers a promising and novel tool for modeling multifactorial diseases from high-dimensional datasets that leverages strengths of ensemble methods for predictive performance, while also providing interpretable explanations for its predictions.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.